Skip to main content
. 2012 Nov 21;72(11):1830–1835. doi: 10.1136/annrheumdis-2012-202460

Table 3.

Clinical response (SRI) to treatment at weeks 12 and 24: overall ITT analysis

Lupuzor
Group 1 (200 μg every 4 weeks) Group 2 (200 μg every 2 weeks) Group 3 (placebo)
Week 12 n=49 n=51 n=47
Responders, n (%) 26 (53.1) 23 (45.1) 17 (36.2)
p=0.048 p=0.18
Week 24 n=49 n=51 n=49
Responders, n (%) 29 (59.2) 30 (58.8) 26 (53.1)
p=0.27 p=0.28

p Values compare Lupuzor with placebo. Drop-outs are considered as non-responders.

ITT, intention-to-treat; SRI, SLE Responder Index.